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Introduction: The transforming growth factor beta (TGF-β) signalling pathway is known to control human breast
cancer invasion and metastasis. We demonstrate that the zebrafish xenograft assay is a robust and dependable
animal model for examining the role of pharmacological modulators and genetic perturbation of TGF-β signalling
in human breast tumour cells.
Methods: We injected cancer cells into the embryonic circulation (duct of cuvier) and examined their invasion and
metastasis into the avascular collagenous tail. Various aspects of the TGF-β signalling pathway were blocked by
chemical inhibition, small interfering RNA (siRNA), or small hairpin RNA (shRNA). Analysis was conducted using
fluorescent microscopy.
Results: Breast cancer cells with different levels of malignancy, according to in vitro and in vivo mouse studies,
demonstrated invasive and metastatic properties within the embryonic zebrafish model that nicely correlated with
their differential tumourigenicity in mouse models. Interestingly, MCF10A M2 and M4 cells invaded into the caudal
hematopoietic tissue and were visible as a cluster of cells, whereas MDA MB 231 cells invaded into the tail fin and
were visible as individual cells. Pharmacological inhibition with TGF-β receptor kinase inhibitors or tumour specific
Smad4 knockdown disturbed invasion and metastasis in the zebrafish xenograft model and closely mimicked the
results we obtained with these cells in a mouse metastasis model. Inhibition of matrix metallo proteinases, which are
induced by TGF-β in breast cancer cells, blocked invasion and metastasis of breast cancer cells.
Conclusions: The zebrafish-embryonic breast cancer xenograft model is applicable for the mechanistic understanding,
screening and development of anti-TGF-β drugs for the treatment of metastatic breast cancer in a timely and
cost-effective manner.Introduction
Transforming growth factor-β (TGF-β) system signals via
serine/theronine kinase receptors and intracellular Smad
transcriptional mediators to regulate a large number of
biological processes [1]. Alterations of the TGF-β signal-
ling pathway are implicated in many human diseases, in-
cluding cancer (reviewed in [2]). Prior to tumour initiation
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reproduction in any medium, provided the ora tumour suppressor; however at later stages it functions
as a tumour promoter. As tumours develop they switch
their response to TGF-β and utilise this factor as a potent
promoter of cell motility, invasion, metastasis, and tumour
stem cell maintenance (reviewed in [3,4]). Multiple signal
transduction pathways, involving a range of signalling
molecules, determine the effects of TGF-β influence on
multiple aspects of tumour growth and progression. Fur-
ther research on how this cytokine is capable of being a
tumour suppressor turned into a tumour promoter is im-
portant for the development and informed use of poten-
tially powerful TGF-β targeted therapies [5].
Over the past decade, zebrafish (Danio rerio) has be-
come an important animal model for cancer, immune and
stem cell research [6-8]. Zebrafish are ideal for identifyingl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tumour progression. There is conservation between zebra-
fish and mammals of many molecular and cellular compo-
nents that operate during tumourigenesis. In addition, the
physiological responses in zebrafish embryo to a wide
range of pharmacologically active compounds are compar-
able to those in mammalian systems [9]. High resolution
in vivo analysis of tumour progression and the interactions
between tumour cells and the host microenvironment
[10,11] can be readily performed due to the transparency
of zebrafish, in combination with the availability of various
tissue-specific fluorescent reporter transgenic lines [12,13].
Several tumour transplantation assays with human and
mammalian cells to study different aspects of tumour ma-
lignancies in embryo and adult zebrafish, such as tumour
cell migration, proliferation, angiogenesis and tumour cell
extravasation [6,12,14-16] have been developed. Many of
these assays are simplistic and are limited to one selected
step of tumour development, and thus, do not represent
the full complexity of tumourigenesis in one model. A
rapid and reproducible zebrafish embryonic xenograft
model for simultaneous formation of a localized tumour
and experimental micrometastasis, by intravascular injec-
tion of tumour cells into the blood circulation of zebra-
fish embryos, has been recently described by the group of
Snaar-Jagalska [17]. They have shown that with non-
invasive high-resolution imaging, the critical steps of
tumour progression, including tumour vascularisation and
tissue invasion, can be characterized.
We applied this xenograft model and focused our
studies on the effect of misregulation of TGF-β signal-
ling components in breast cancer invasion and metastasis.
We have used breast cancer cell lines of which, in previous
studies, we and others have shown that the invasive and
metastatic behaviour in spheroid invasion and mouse
xenograft models is dependent on TGF-β [18]. We dem-
onstrated that the invasive and metastatic behaviour,
corresponding with the cell grade of malignancy can be
recapitulated within the zebrafish. Moreover, the effects
obtained after inhibiting with TGF-β receptor and Smad
function in fish mimicked the effects observed in mice.
Importantly, an effector role for matrix metalloprotein-
ases (MMPs) in invasion and metastasis was demonstrated
in this model. The differences in invasive properties upon
dysregulation of TGF-β signalling components and its
effectors are seen with clarity unprecedented in other
animal models, making it applicable in a pipeline for new
drugs discovery.
Material and methods
Reagents and cell culture
Human cell lines (293 T, 3 T3, and MDA-MB-231) were
maintained cultured at 37°C in DMEM-high glucose
containing L-glutamine, 10% FCS and 1:100 Penicillin/Streptomycin (Pen/Strep) (Gibco, Invitrogen, Blijswijk,
Netherlands). The MCF10A-derived breast epithelial cell
lines M1, M2, and M4 (MCF10A or M1, MCF10AT1k.cl2
or M2, and MCF10CA1a.cl1 or M4) were maintained as
previously described [19]. Zebrafish cell lines, ZF4 and
PAC2 were maintained according to the American Type
Culture Collection (Manassas, VA, USA) recommendations.
Briefly, zebrafish cells were cultured at 28°C in DMEM con-
taining L-glutamine, 10% FCS and 1:100 Pen/Strep (Gibco,
Invitrogen, Blijswijk, Netherlands). The 293 T, 3 T3, MDA-
MB-231, ZF4 and PAC2 cells were originally obtained from
American Type Culture Collection. MCF10CA1a.cl1 (M4)
cells were kindly provided by Dr Fred Miller (Barbara Ann
Karmanos Cancer Institute, Detroit, MI, USA).
Luciferase experiments
Cells were plated on day 0 in 24-well plates and trans-
fected with constant total concentration of DNA in a
given experiment on day 1. Cells were transfected with a
TGFβ/Smad3-responsive promoter, firefly luciferase tran-
scriptional reporter construct, CAGA12-luc [20], in con-
junction with a β-galactosidase control for transfection
efficiency. Cells were also transfected with zTGF-β1, re-
verse zTGF-β1, or an empty vector control. The same
day, cells were either untreated or treated with TGF-β
1 ng/mL for 24 h. Cell lysates were harvested on day 2
and luciferase activity was measured. Experiments were
performed in triplicate and repeated twice. The CAGA12
promoter-driven luciferase activity was normalized to the
β-galactosidase activity, averaged, and plotted. Luciferase
results were analysed by one-way analysis of variance
(ANOVA). Representative experiments are shown.
Fluorescent cell labelling
Non-fluorescent cells were labelled with the fluorescent
cell tracker CM-DiI (Invitrogen, Blijswijk, Netherlands)
according to the manufacturer’s instructions. Briefly, cells
were grown to confluence in a T25-cm2 dish, and trypsi-
nized. Subsequently, cells were washed with PBS, trans-
ferred to 1.5 ml Eppendorf tubes and centrifuged 5 min, at
1200 rpm. Cells were re-suspended in PBS containing
CM-Dil (4 ng/ul final concentration). Cells stained with
CM-Dil were incubated for 4 minutes at 37°C and then
15 minutes at 4°C. After this period cells were centri-
fuged for 5 minutes at 1,200 rpm, the supernatant
discarded and cells re-suspended in media, centrifuged
again and washed two times with PBS. Cells were sus-
pended in DMEM or PBS for injection into the embryos.
Lentiviral transduction
Lentivirus was produced by co-transfecting an mCherry
PLKO plasmid and helper plasmids pCMV-VSVG, pMDLg-
RRE (gag/pol), and pRSV-REV into HEK293T cells. Cell
supernatants were harvested 48 h after transfection and
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lines, cells were infected at 20% confluence for 24 h with
lentiviral supernatants diluted 1:1 with normal culture
medium in the presence of 5 ng/mL polybrene (Sigma,
Zwijndrecht, Netherlands). At 24 h after infection, cells
were placed under puromycin (1 μg/ml) selection for one
week, or collected for injection at 1 day after infection.
Zebrafish maintenance
The Institutional Committee for Animal Welfare of the
Leiden University Medical Center (LUMC) approved this
study. Zebrafish and embryos were raised, staged and
maintained according to standard procedures. The trans-
genic line Tg(fli1:GFP) was used in this study [11,12].
Embryo preparation and tumour cell implantation
Dechorionized 2 days-post fertilisation (dpf) zebrafish em-
bryos were anaesthetized with 0.003% tricaine (Sigma) and
positioned on a 10-cm Petridish coated with 3% agarose.
Single cell suspensions of fluorescent mammalian cells
were re-suspended in PBS, kept at room temperature
before implantation and implanted within 3 h. The cell
suspension was loaded into borosilicate glass capillary
needles (1 mm O.D. × 0.78 mm I.D.; Harvard Apparatus)
and the injections were performed using a Pneumatic
Picopump and a manipulator (WPI, Stevenage, UK). Ap-
proximately 400 cells (manually counted) were injected at
approximately 60 μm above the ventral end of the duct of
Cuvier (DoC), where the DoC opens into the heart. After
implantation with mammalian cells, zebrafish embryos
(including non-implanted controls) were maintained at
33°C, to compromise between the optimal temperature re-
quirements for fish and mammalian cells [21]. For each
cell line or condition, data are representative of at least
three independent experiments with at least fifty embryos
per group. Experiments were discarded when the survival
rate of the control group was less than 80%.
In vivo toxicity test of chemical compounds
Chemical compounds were added to the eggwater at 2 dpf for
toxicity tests, or 24 h post implantation (hpi) for treatment,
and refreshed every second day. Chemical compounds were:
LY-294002 (Cell Signaling, Leiden, Netherlands), SB-431542
(Sigma, Zwijndrecht, Netherlands) and Gm6001 (Calbio-
chem, Amsterdam, Netherlands). For toxicity tests, embryo
survival or malformation was scored daily. For treatment,
after 5 days embryos were fixed overnight in 4% buffered
paraformaldehyde (PFA) at 4°C. Embryos were placed in a
glass-bottom 96-well plate (Greiner Bio One GmbH, Frick-
enhausen, Germany), and imaged as described.
Microscopy and analysis
Fixed embryos were imaged in PBS-Tween. Fluorescent
image acquisition was performed using a Leica MZ16FAstereo microscope, or a Leica SP5 STED confocal micro-
scope. Confocal stacks were processed for maximum inten-
sity projections with Leica software or Adobe Photoshop
CS4 software. Images were adjusted for brightness and
contrast using Adobe Photoshop CS4. Overlays were cre-
ated using Adobe Photoshop CS4.
Immunohistochemistry
Whole-mount immunohistochemistry of zebrafish was car-
ried out as described [22]. Primary anti-phospho-Smad2
(p-Smad2) antibodies (Millipore, Amsterda, Netherlands)
(1:200 dilution) and secondary antibodies (Alexa 647 anti-
mouse; Invitrogen, Blijswijk, Netherlands) (1:200 dilution)
were used for detection. Immunohistochemistry of zebra-
fish cell lines required cells to be plated in 12-well plates on
coverslips. The methods for immunohistochemical staining
of p-Smad2 are described in the manufacturer’s instruc-
tions. In brief, the slides were incubated with p-Smad2 anti-
body (1:2,000) overnight at 4°C, washed with PBS, and
incubated with the secondary antibody (Alexa 488).
Results
Invasion and micrometastasis formation of human breast
cancer cell lines in zebrafish
Human cancer cell lines have provided a rich source of
propagatable material for the molecular and cellular char-
acterization of cancer pathogenesis. The MCF-10A series
of cell lines (MCF10A or M1, MCF10AT1k.cl2 or M2, and
MCF10CA1a.cl1 or M4) represents the spectrum of pro-
gression from relatively normal breast epithelial cells (M1),
pre-malignant (M2) to high-grade carcinoma capable of
metastasis (M4) [19]. The MDA-MB-231 cell line is used
extensively for the study of hormone-independent breast
cancer. It is capable of forming tumours in immune-
deficient mice, and has a high metastatic potential, thereby
providing xenograft models for study cancer development
in vivo [23]. These cell lines were fluorescently labelled, ei-
ther with mCherry stable transfection or CmDiI, and were
transplanted into the DoC of 2-day-old zebrafish embryos
(Figure 1A) to study invasive and metastatic behaviour
in vivo. Injection of invasive or metastastic cells directly
into the blood circulation allows the cells to be distrib-
uted throughout the organism with the blood flow. This
assay models the later stages in successful metastasis,
without the formation of a primary tumour site [17].
Immediately after injection, the implanted cells hemato-
genously disseminate in the embryo (Figure 1B). Within
the first 3 h, the tumour cells arrest within the dorsal
aorta and caudal vein, and also some cells may penetrate
into the smaller optic veins and the inter-segmental ves-
sels (Figure 1B). The breast cancer cells M1 (low meta-
static potential), M2 (moderate metastatic potential),
M4 (high metastatic potential) and MDA-MB-231 (very




























Figure 1 (See legend on next page.)
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Figure 1 Schematic of embryonic zebrafish and injections into the ducts of Cuvier. (A) Fluorescent microscopy image of a 48 h-post
fertilization (hpf) Tg(fli1:GFP) zebrafish. The boxed area represents the ideal injection site. The cells will then enter into the circulatory loop, as
shown in the light microscopy image. The dorsal aorta, caudal vein, and ducts of Cuvier (DoC) are emphasized with red. (B) mCherry-labelled
MDA-MB-231 cells injected into the DoC immediately disseminate throughout the vasculature. Image was taken 2 h-post implantation (hpi). A
magnification of the tail region, displaying the vasculature (green), and cells (red) is shown. (C) Typical images of the various stages of cell survival
in the zebrafish embryo. Only cells with metastatic potential are capable of undergoing invasion and micrometastasis. MDA-MB-231 cells (red) are
shown. (D) A light microscopy image of the tail fin after injection with fluorescent polystyrene beads. Beads become lodged within the end of
the circulatory loop. (E) MDA-MB-231 cells (red) displayed invasion as singular cells into the collagen fibres of the tail fin (scale bar = 100 μm). M2
and M4 (shown) displayed an invasive phenotype in with cells collectively cluster together (scale bar = 50 μm). (F) Only tumourigenic cells were
capable of displaying invasive properties in the fish. MDA-MB-231 cells were compared to the motile, but non-invasive 3 T3 cells, and the weakly
tumorigenic 293 T cells. Scale bar = 100 μm. Data are representative of three independent experiments with at least 50 embryos per group.
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patterns were also observed from injection of 15-μm fluor-
escent polystyrene microspheres (Figure 1D). Both, cells
and polystyrene microspheres, lodge at the end of the
circulatory loop (the point where the single dorsal aorta
continues into the tail and then turns 180° at its most
caudal end to empty into the caudal vein). These data
suggest that this process is independent of the tumouri-
genic property of the implanted cells. After 24 h, we ob-
served disappearance of the fluorescent signals from the
transplanted cells, indicating regression of extravasated
cells without initiating proliferation. Importantly, cells
with moderate or high metastatic potential were cap-
able of invading into the neighboring tail fin within 1 dpi
(invasion defined as 3 to 30 cells outside of the vasculature)
and subsequently develop micrometastasis (30+ cells) in
the tail fin (Figure 1C). M1 cells and also the fluorescent
polystyrene microspheres never showed invasion into the
avascular tail fin area.
The phenomenon of mammalian cell motility is im-
portant in the progression of cancer. Interestingly, M2
and M4 cells displayed a different invasive and meta-
static profile than that seen with MDA-MB-231 cells.
MDA-MB-231 cell invasion is visible as singular cells into
the collagen matrix of the caudal tail, whereas M2 and M4
cell invasion is visible as a collective group within the cau-
dal haematopoietic tissue (CHT) (Figure 1E). To explore
the specificity of the events we observe with the invasive
breast cancer cells, we analysed the behaviour of non-
tumourigenic 3 T3 mouse embryonic fibroblasts and
weakly tumourigenic 293 T human embryonic kidney cells
within the zebrafish embryonic model. Upon transplant-
ation into the DoC of 2-day-old zebrafish embryos, as
above, neither the 3 T3 (n = 187), nor the 293 T (n = 162)
cell lines showed invasion at 6 dpi (Figure 1F). MDA-MB-
231 (n = 174) cells, transplanted as a positive control,
showed invasion after 12 h, and 54% of fish displayed
invasion at 6 dpi. The negative control, 293 T (n = 162),
did not display invasion or micrometastasis. These data
imply that the process of cell invasion and metastasis
within a zebrafish model occurs in a specific manner andis not merely an artefact, nor is it a passive process. Im-
portantly, the behaviour of relatively benign M1, to pre-
malignant M2 and metastatic M4 and MDA-MB-231
cells as determined in mouse and spheroid invasion as-
says [18,19,24] correlates with the relative state of aggres-
siveness of these four cell lines in the zebrafish embryo
xenograft assay.
Zebrafish and human TGF-β act cross species
Previously, we and others have shown that TGF-β has a
critical role in driving invasion of M2 and M4 cells [18,25]
and metastasis of MDA-MB-231 cells to bone [26-28].
Considering that the zebrafish outperforms existing mouse
models with respect to high-resolution imaging of the dy-
namic process of cell invasion during cancer progression,
and is easily amenable to genetic and pharmacological
screening, we therefore set out to investigate whether the
xenograft breast cancer assay in zebrafish embryos can be
used to determine the role of TGF-β signalling compo-
nents in breast cancer invasion and metastasis.
Our assay system is heterologous. However, as zTGF-β1
is highly homologous to higher vertebrates (Additional
file 1: Figure S1A) [29], the ligands may act cross species;
host-derived zTGF-β may signal on human tumour cells,
and tumour-cell-derived TGF-β may bind and activate
TGF-β receptors on host zebrafish cells (Additional file 1:
Figure S1B-D). The zTGF-β1 construct was capable of in-
ducing TGF-β Smad3/Smad4 mediated luciferase output
significantly in two human cell lines (P = 0.05) (Additional
file 1: Figure S1 B and C). This indicates that the zTGF-
β1 interacts with the human TGF-β receptor signalling
pathway. Moreover, human TGF-β is capable of inducing
phosphorylated Smad2 (pSmad2), and subsequent nuclear
localisation of pSmad2, in zebrafish cell lines, ZF4 and
PAC2 (Additional file 1: Figure S1D). Together, these data
indicate that upon injection of human tumour cells into
zebrafish embryos, the two heterologous cell types may
mutually communicate with each other via TGF-β recep-
tor signalling. Furthermore, as breast cancer tumour cells,
such as MCF10A and MDA-MB-231, express TGF-β
themselves [18,30], we cannot exclude that human tumour
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in an autocrine manner.
Small molecular TGF-β type I receptor kinase inhibitors
mitigate invasion of human breast cancer cells in the
zebrafish model
TGF-β type I receptor kinase inhibitors have been devel-
oped that selectively inhibit TGF-β responses [5], includ-
ing the induction of breast cancer cell migration, epithelial
to mesenchymal transition, and invasion and metastasis to
bone [31,32]. Zebrafish have been used extensively for
chemical screens in experimental biology [33]. Small mol-
ecules can be added directly to the water and diffuse into
the zebrafish embryo [34]. We therefore set out to investi-
gate the effect of addition of TGF-β type I kinase inhibi-
tors on breast cancer invasion and metastasis in zebrafish
xenograft assay. First we subjected the zebrafish to differ-
ent doses of SB-431542 [31,32] or LY-294002 [35] TGF-β
receptor kinase inhibitor (TRKI). Each inhibitor was added
to the zebrafish embryos 48 hpf, and monitored for 5 days.
At the doses to 5 μM or 2.5 μM of SB-431542 or LY-
294002, respectively, no deformities or very few deform-
ities were observed. Extensive malformation and death of
the embryos occurred at higher doses. The typical malfor-
mations seen from intolerable doses of small molecular
TRKIs included pericardial and yolk-sac oedema, altered
architecture of the dorsal and caudal fins, and also short
anterior-posterior body axis (Figure 2A). These effects may
be (in part) on target, as deletion of TGF-β receptors also
cause yolk-sac defects and pericardial effusion [36,37].
Human breast cancer cell lines, MDA-MB-231 and the
MCF-10 series (M1, M2, and M4) were treated with or
without the inhibitors for 24 h prior to transplant-
ation into the zebrafish embryo (SB-431542 = 5 μM, LY-
294002 = 5 μM or a vehicle control). Xenografted zebrafish
were treated with the doses of the small molecular in-
hibitors found to be tolerable (SB-431542 = 5 μM, LY-
294002 = 2.5 μM, or a vehicle control for 6 dpi). The
zebrafish embryo water was changed every second day.
Targeting the TGF-β pathway with small molecular inhibi-
tors proved effective and reduced both invasion of the can-
cer cells, and also the development of micrometastasis
(Figure 2B-C and Additional file 2: Figure S2). Further-
more, MDA-MB-231 cells that were not pretreated with
the small molecular TRKI, but only treated after trans-
plantation, also showed a reduction of invasion and micro-
metastasis (Additional file 3: Figure S3).
Phospho-Smad2 expression can be switched off with small
molecular inhibitors targeting the TGF-β signalling pathway
Upon TGF-β type I receptor activation, Smad2 is phos-
phorylated at carboxy (C)-terminus on two serine resi-
dues by the TGF-β type I receptor [38,39]. C-terminal
pSmad2 corresponds to activated Smad2, which is capableof forming a nuclear heteromeric complex with Smad4,
which is transcriptionally active, and thus pSmad2 can be a
useful tool to interrogate the activation state of the TGF-β/
Smad signalling pathway. As such, zebrafish transplanted
with MDA-MB-231 or M4 cells, treated with and without
SB-431542 or LY-294002 (as above) were subjected to im-
munohistochemistry to determine if pSmad2 in tumour
cells had been prevented and/or inhibited upon inhibitor
treatment. Zebrafish that displayed invasion, regardless of
treatment, were positive for pSmad2 (Figure 3A). This
posed a conundrum, as it may be expected that invasive or
metastatic cells that have overcome the inhibition of TGF-β
would continue to phosphorylate Smad2, but cells that
were sensitive to the treatment would not invade, and thus
are not able to be examined for pSmad2. Therefore, zebra-
fish transplanted with MDA-MB-231 or M4 cells were kept
without treatment for 5 days, and then treated with SB-
431542, LY-294002 or a vehicle control for up to 24 h. This
system allowed the cells to invade and metastasise, giving
us the best option to visualise the impact small molecular
inhibitors of the TGF-β pathway have on the zebrafish
xenograft model. As seen in Figure 3B, phosphorylation of
Smad2 can be effectively switched off in breast cancer cells,
MDA-MB-231, when treated with a TKRI, for as little as
1 h. Thus, pharmacological inhibition of TKRI activity in-
hibits TGF-β/Smad2 signalling of transplanted breast
tumour cells in zebrafish and inhibits their invasiveness.
Smad4 knockdown in breast cancer cells inhibits their
invasion and metastasis in the zebrafish model
Next we set out to examine the effect on breast cancer in-
vasion and metastasis by antagonizing TGF-β/Smad signal-
ling in breast cancer cells in a cell-autonomous manner.
MDA-MB-231 cells with stable transfection of shRNA tar-
geting Smad4 have been previously shown to inhibit the
frequency of bone metastasis in nude mice by 75% and sig-
nificantly increased metastasis-free survival in intracardiac
mouse models [27]. Using the zebrafish embryo xenograft
model, MDA-MB-231 cells stably transfected with shRNA
targeting Smad4, or the empty vector, were examined for
invasion. Similar to the mouse model, at 6 dpi, Smad4
knockdown provided a significant reduction of invasion
(n = 179) (Figure 4A). Furthermore, given the relatively
short time required to visualise invasion and metastasis,
transient transfection of siRNA may be a useful tool. To
examine the effect of siRNAs targeting Smad4 on invasion,
MDA-MB-231, M2, and M4 cells were transiently trans-
fected with Smad4-specific siRNA, or a scrambled control.
Significant inhibition of invasion was seen in each cell line
(Figure 4B and data not shown).
MMP inhibition
MMPs are known to have tumour-promoting and tumour-
inhibitory effects but unfortunately, several clinical trials
AVehicle treated control Oedema Oedema and altered body axis
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Figure 2 Small molecular TGF-β receptor kinase inhibitor (TKRI) inhibited invasion of human breast cancer cells. (A) Typical deformities
seen with higher doses of SB-431542 and LY-364947. (B) Graphical representation of the percentage of embryonic zebrafish with invading breast
cancer cells. Each group contained the non-invasive M1 cells as a control. The TKRIs were added directly to the fish water every second day.
MDA-MB-231 and M2 cells are shown. Errors bars represent standard deviation. (C) Representative images taken at 5 days post injection. MDA-MB-231
cells have left the vasculature and are located within the collagen fibres of the tail fin. M2 cells have moved out of the vasculature and into the caudal
haematopoietic tissue. All data are representative of three independent experiments with at least 50 embryos per group. Scale bar = 50 μm.
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promising effects [40]. The specific MMP2/9 Inhibitor II,
has been shown to mitigate TGF-β induced invasion ofbreast cancer cells [18]. Human breast cancer cell lines,
MDA-MB-231 and the MCF-10 series (M1, M2, and M4)









Figure 3 Small molecular TGF-β type 1 receptor (TKRI) reduce expression of phosphoylated (p)Smad2. pSmad2 expression of MDA-MB-231 cells
that were not treated for 5 days post implantation (dpi), and then were treated for 1 h with (A) vehicle or (B) SB-431542. The SB-431542-treated cells
were negative for TKRI activation. Data are representative of three independent experiments with at least 50 embryos per group. Scale bar = 100 μm.
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fish embryo. The xenografted zebrafish were treated
with 50 nM of MMP2/9 Inhibitor II, a dose of the small
molecular inhibitor found to cause minimal malforma-
tion and death, or a vehicle control for 6 dpi. The zebra-
fish embryo water was changed every second day.
Inhibiting MMP2 and MMP9 halted the invasion of
metastatic breast cancer cells in the embryonic zebrafish
(Additional file 4: Figure S4).
GM6001 is an MMP inhibitor; also known as Galardin
or Ilomastat, it has been shown to suppress invasion of
MDA-MB-231 cells in a three-dimensional collagen spher-
oid assay [41], and MCF10A M4 cells [18]. MDA-MB-231
and the MCF-10 series (M1, M2, and M4) were treated
with or without the inhibitors for 24 h prior to transplant-
ation into the zebrafish embryo (GM6001 = 10 μM). Xeno-
grafted zebrafish were treated with the doses of the small
molecular inhibitors found to be tolerable (GM6001 =
5 μM), or a vehicle control for 6 dpi. The zebrafish embryo
water was changed every second day. Targeting the TGF-β
pathway with small molecular inhibitors proved effectiveand reduced the invasion of the cancer cells (Figure 5 and
Additional file 5: Figure S5).Discussion
This study used the zebrafish xenograft assay by inject-
ing malignant breast cancer cells into the embryonic
circulation, and monitoring their invasion into the avascu-
lar collagenous tail fin, as a robust and dependable animal
model for examining the role of pharmacological modu-
lators and genetic perturbation of TGF-β signalling in
human tumour cells. Upon injection into the DoC, we
observed that breast cancer cells dispersed immediately
throughout the embryo via the circulating blood system,
extravasated and invaded neighbouring tissue at specific
tail-fin sites and formed micrometastasis within 6 days (as
previously described in [17]). We have shown that blocking
the TGF-β pathway using various methods of inhibition -
and at various stages of the pathway - results in a signifi-
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Figure 4 Smad4 knockdown by shRNA or siRNA in breast cancer
cells. (A) MDA-MB-231 with stable knockdown of Smad4 displays a
reduced amount of invasion. A representative image from day 6,
showing cells located in the collagen fibres of the tail is shown.
(B) Transient knockdown of Smad4 in MDA-MB-231 cells was also
capable of inhibiting the amount of invasion over 5 days. A
representative image from day 5 is shown. Scale bar = 100 μm. Data
are representative of three independent experiments with at least 50
embryos per group. Error bars represent standard deviation.
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http://breast-cancer-research.com/content/15/6/R106Invasion and micrometastasis were only observed from
breast cancer cells with metastatic potential. Interest-
ingly, we found that M2 and M4 cells formed clusters of
invasive cells mainly in the CHT region, where they are
capable of proliferation (data not shown). In contrast,
MDA-MB-231 cells were visible as single cells that mi-
grated much more aggressively than M2 and M4 cells
into the tail fin. It will be an interesting area of future re-
search to determine what determines the phenotypic dif-
ferences of cell migration. A recent publication has shown
that ectopic expression of Slug or Snail is capable of pro-
moting invasion of single, rounded amoeboid cells in vitro
[42]. Furthermore, when M2 cells with Snail or Slug over-
expression were implanted into the embryonic zebrafish
xenograft model, single-cell invasion was also seen. This
would suggest that epithelial to mesenchymal transition
(EMT) is a potential requirement for single-cell migration
into the tail fin. The degree of EMT within the cancer cells
may also effect the communication of these cells with
their environment.
Importantly, invasion could be seen at the single-cell
level in the zebrafish embryo. The differences between
invasive phenotypes (cells that cluster tightly together as
opposed to cells that do not) are not able to be detected
in larger animal models. To date, the most effective sys-
tem to analyse the differences between the invasive phe-
notypes uses in vitro methods [43]. It is only due to the
small, transparent nature of the zebrafish that such inva-
sion could be seen at single-cell level in an animal model.
The ability to view early-stage cell invasion in vivo provides
an opportunity to examine the cell-cell junctions of tu-
mours, and their environment.
We found that injected MDA-MB-231 cells showed
active TGF-β/Smad signalling in vivo as measured by
pSmad2 staining. Furthermore, we found that zTGF-β
may act on human tumour cells, and tumour-cell-derived
TGF-β may act on the host zebrafish. The confinement of
pSmad2 staining to the tumour cells, and ability to inhibit
metastasis by blocking TGF-β signalling in a tumour cell
autonomous manner suggests that TGF-β produced by
tumour cells acts on tumour cells to mediate cell invasion
and metastasis. We were surprised not to see elevated
pSmad2 staining in the host tissue surrounding the tumour
cells if they secrete high levels of TGF-β. If zTGF-β would
have contributed to mediating the invasion and metastatic
response we would have also expected elevated pSmad2
staining in the host tissue surrounding the tumour. Fur-
ther studies in zebrafish may highlight the effect that the
stromal environment has on the early stages of metastatic
development.
The zebrafish model described here allows simultan-
eous monitoring of tumour cell extravasation, invasion
and micrometastasis in vivo within one week of implant-




































































Figure 5 Small molecular inhibition of matrix metalloproteinases (MMPs). (A) Graphical representation of M2 and MDA-MB-231 cells treated
with the MMP inhibitor GM6001 over 5 days. Inhibition of MMP expression reduces the amount of invasion of breast cancer cells. (B) Representative
images of MDA-MB-231 cells that have migrated to the collagen fibres or M2 cells that have located to the caudal hematopoietic tissue.
Scale bar = 100 μm. Data are representative of three independent experiments with at least 50 embryos per group. Errors bars represent
standard deviation.
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http://breast-cancer-research.com/content/15/6/R106have been transplanted into the hindbrain [21], liver, yolk
[44-51], or the peritoneal cavity [11,47,52] in order to de-
termine the invasive or metastatic potential of cancers. Al-
though these techniques have many advantages, they also
have limitations. Many of these studies show cell invasion
and metastasis, which may be explained, not by the inva-
sive properties of the cell, but by the accidental injection of
cells into the blood circulation of the embryo. In some
cases, invasion was shown as a singular cell that was lo-
cated within the dorsal aorta. For the zebrafish embryo to
be considered a dependable tool for use in investigatingthe process of invasion and metastasis of cancer cells, we
believe that injecting cells into the DoC provides the most
reliable assay. In our model, micrometastasis formation
only occurs following the MDA-MB-231 cell invasion into
the tail fin from the posterior end of the CHT. Previous
work has shown that this invasion site is determined by
the physiologic migration of neutrophils, thus supporting
the so-called seed-and-soil hypothesis of tumour metastasis
[17]. Furthermore, by limiting the area that we look at for
invasive cells, the amount of human error is reduced.































Figure 6 Blocking the transforming growth factor β (TGF-β)
signalling pathway. Blocking various aspects of the TGF-β signalling
pathway is capable of reducing the invasive properties of breast
cells in vivo. The embryonic zebrafish model provides an ideal system
for using chemical inhibition, siRNA, or shRNA, to target the TGF-β
signalling pathway. MMP, matrix metalloproteinase.
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http://breast-cancer-research.com/content/15/6/R106a metastasis, has been shown to be controlled by the
tumourigenic property of disseminated cells (as shown in
Figure 2), and the microenvironment [17]. However, it is
important that the conditions are optimised for each cell
type, including cell number, in order that the results are
reliable and reproducible.
This unique animal system provides a visual window
into the metastastic process in a live vertebrate animal,
with unprecedented clarity. The experiments described
here establish the basis for the future development of a
screening methodology for drugs that inhibit invasion
and metastasis of breast cancers. Furthermore, the data
also shows that transient transfection of siRNAs may be
used to examine the effect of invasion and metastasis
(Figures 5 and 6). We have previously used the embryonic
zebrafish xenograft model to study novel regulators of the
TGF-β signalling pathway, TNF receptor-associated factor
4 (TRAF4) [53] and ubiquitin-specific protease 4 (USP4)
[54], as well as the tumour suppressor FAF1 [55], which in-
teracts with the FAS ligand. The zebrafish offers a promis-
ing future for functional studies of breast cancers.
Studies of the efficacy of pharmacology and toxicology
in murine xenograft models normally use tumour growth,
body weight loss and mortality as parameters of toxicity.These studies are cumbersome and time consuming, and
drug activity against xenografts does not always correlate
with its clinical activity [56]. As seen in Figure 2, the
parameters of drug dosage can be quickly and easily visual-
ized in the zebrafish. Furthermore, small molecular com-
pounds can be added directly to the environment of the
zebrafish, which can be less stressful to the both the ani-
mal, and technician, compared to the injection techniques
used in rodent models.
One potential therapy using MMP inhibition was ana-
lysed in this study using the zebrafish model. MMPs have
a critical role in inflammation and tumourigenesis and
appear to be ideal as a drug target. Many inhibitors have
been developed, and several have gone as far as clinical
trials in cancer patients. Unfortunately, though these
inhibitors have showed promising effects in preclinical
studies, the same agents did not have such a positive out-
come in cancer treatment [2,57]. This highlights the issue
of complexity that the MMPs play in cancer progression.
In this study, we used GM6001, a broad-spectrum MMP
inhibitor. GM6001 has been previously tested in the devel-
opment of zebrafish [53,54]. These studies have shown the
importance of MMPs during embryonic development [54]
and fin regeneration [53]. We were able to show that
MMP inhibition was capable of reducing the amount of in-
vasion and metastasis of human mammary carcinoma cells
in the zebrafish. It must be noted that MMP inhibition was
initiated at the early stage of cancer metastasis. It had been
previously hypothesised that, as MMPs contribute to mul-
tiple stages of tumour progression, MMP inhibition is most
beneficial at the early stages and the therapeutic benefit de-
creases as the disease progresses [58]. Accordingly, many
studies have shown that disruption of the TGF-β signalling
early in metastasis can substantially reduce metastasis bur-
den and that the effect becomes less effective when lesions
become well-established [59-61]. It has been argued that
well-established bone lesions may become less dependent
on bone destruction and TGF-β signalling and, as a conse-
quence, become less sensitive to TGF-β inhibitors [59].
Conclusion
The dysregulation of TGF-β is well known in human
breast cancer. Thus, the TGF-β pathway is an attractive
therapeutic target. With its own advantages and disadvan-
tages, the zebrafish embryo xenograft model represents a
novel tool for investigating the tumour invasion/metastasis
process. Furthermore, the zebrafish embryo xenograft
model is exploitable for drug discovery and gene targeting.
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Additional file 1: Figure S1. z-Transforming growth factor-β (TGF-β) is
highly homologous to higher vertebrates. (A) A sequence analysis of the
mature peptide from the human and zebrafish is compared. (B) Zebrafish
Drabsch et al. Breast Cancer Research 2013, 15:R106 Page 12 of 13
http://breast-cancer-research.com/content/15/6/R106(z)-TGF-βR transfected into 293 T cells was capable of inducing transcription,
as indicated by the CAGA luciferase assay. (C) A similar result was also seen
with MDA-MB-231 cells; P = 0.05. (D) Human TGF-β 1 was capable of acti-
vating the TGF-β signalling pathway in the zebrafish cell lines ZF4 and
PAC2. Errors bars represent standard deviation.
Additional file 2: Figure S2. (A) Graphical representation of the
percentage of embryonic zebrafish with invading M4 breast cancer cells.
The non-invasive M1 cells were used as a control. Error bars represent
standard deviation. (B) Representative images taken at 5 days post injection.
Scale bar = 50 μm.
Additional file 3: Figure S3. SB-431542 acts as a strong TGF-β receptor
kinase inhibitor (TKRI). (A) MDA-MB-231 cells, pretreated with 5 μM SB-431542
for 24 h were transplanted into 48-hours post fertilization (hpf) zebrafish
embryos. No subsequent treatment of SB-431542 was given. The level of
invasion was measured over 5 days. (B) MDA-MB-231 cells were transplanted
into the 48-hpf zebrafish embryos, and treated with 5 μM SB-431542 every
second day. The level of invasion was measured over 5 days. Error bars
represent standard deviation.
Additional file 4: Figure S4. Small molecular inhibition of matrix
metalloproteinase (MMP)2 and MMP9. Graphical representation of M2,
M4 and MDA-MB-231 cells treated with the MMP2/9 Inhibitor II over
5 days. Inhibition of MMP expression reduces the amount of invasion of
breast cancer cells. Error bars represent standard deviation.
Additional file 5: Figure S5. Small molecular inhibition of matrix
metalloproteinase (MMP) with GM6001. Graphical representation of M4
cells treated with the general MMP inhibitor over 5 days. Inhibition of
MMP expression reduces the amount of invasion of breast cancer cells. A
representative image is included. Scale bar = 100 μm. Error bars represent
standard deviation.
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